Clinical Trial Update: Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Sym021 in combination with Sym022 or Sym023 (and with Irinotecan in some arms) in patients with recurrent advanced selected solid tum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Irinotecan (Irinotecan)
• Sym021
• Sym022
• Sym023

Snippet

Sponsor: Symphogen A/S | Conditions: Metastatic Cancer, Solid Tumor | Phase 1 | Status: COMPLETED